消癌平联合白蛋白紫杉醇+卡铂治疗晚期肺癌的效果  

Xiaoaiping combined with albumin paclitaxel and carboplatin for the treatment of advanced lung cancer

作　　者：杨李姗 杜晓亮 史中强 YANG Lishan;DU Xiaoliang;SHI Zhongqiang(Department of Oncology,the First People′s Hospital of Ruzhou,Pingdingshan 467500,China;Department of Geriatrics,the First People′s Hospital of Ruzhou,Pingdingshan 467500,China)

机构地区：[1]汝州市第一人民医院肿瘤内科,平顶山467500 [2]汝州市第一人民医院老年病科,平顶山467500

出　　处：《华夏医学》2025年第2期103-108,共6页Acta Medicinae Sinica

基　　金：河南省医学科技攻关联合共建项目(LHGJ20201069)。

摘　　要：目的探讨晚期肺癌患者经消癌平注射液联合白蛋白紫杉醇+卡铂治疗的效果。方法回顾性选取108例晚期肺癌患者作为研究对象,分为对照组和联合组,每组54例。对照组给予白蛋白紫杉醇+卡铂治疗,联合组给予消癌平联合白蛋白紫杉醇+卡铂治疗。比较两组疾病控制率、中医证候积分、细胞免疫功能指标、血清肿瘤标志物[转化生长因子结合蛋白2(LTBP2)、糖类抗原125(CA125)、CC趋化因子配体11(CCL11)、细胞角蛋白19片段(CYFRA21-1)]水平、不良反应及1年生存率。结果联合组疾病控制率、1年生存率较对照组高,不良反应发生率较对照组低,差异均具有统计学意义(P<0.05);治疗后,联合组气短气喘、口干舌燥、咳嗽咳痰、神疲体倦等中医证候积分均低于对照组(P<0.05);治疗后,联合组血清LTBP2、CA125、CCL11、CYFRA21-1、CD8^(+)水平均低于对照组,CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均高于对照组(P<0.05)。结论消癌平联合白蛋白紫杉醇+卡铂治疗可明显提高晚期肺癌患者的疾病控制率,改善患者临床症状、细胞免疫功能及血清肿瘤标志物水平,可提高患者1年生存率,降低不良反应发生率。Objective To investigate the therapeutic effect of Xiaoaiping injection combined with albumin paclitaxel and carboplatin in patients with advanced lung cancer.Methods Retrospective selection of 108 patients with advanced lung cancer as study subjects,divided into the control group and combination group,with 54 cases in each group.The control group were treated with albumin paclitaxel and carboplatin,while the combination group were treated with Xiaocaiping combined with albumin paclitaxel and carboplatin.The disease control rate,traditional Chinese medicine syndrome score,cellular immune function indicators,serum tumor marker levels including transforming growth factor binding protein 2(LTBP2),carbohydrate antigen 125(CA125),CC chemokine ligand 11(CCL11),cytokeratin 19 fragment(CYFRA21-1),adverse reactions,and 1-year survival rate were compared between two groups.Results The disease control rate and 1-year survival rate of the combined group were higher than those of the control group,and the incidence of adverse reactions was lower than that of the control group,with a statistically significant difference(P<0.05).After treatment,the combined group had lower scores for traditional Chinese medicine syndromes such as shortness of breath,asthma,dry mouth and tongue,cough and phlegm,and fatigue compared to the control group(P<0.05).After treatment,the serum levels of LTBP2,CA125,CCL11,CYFRA21-1,and CD8^(+)in the combination group were lower than those in the control group,while the levels of CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)were higher than those in the control group(P<0.05).Conclusion The combination of Xiaocaiping and albumin paclitaxel and carboplatin treatment can significantly improve the disease control rate of advanced lung cancer patients,improve clinical symptoms,cellular immune function,and serum tumor marker levels.It can also increase the 1-year survival rate of patients and reduce the incidence of adverse reactions.

关 键 词：肺癌 紫杉醇 卡铂 疗效 生存率 

分 类 号：R734.2[医药卫生—肿瘤]